Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2013-A00744-41 | Other Identifier | ANSM |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Rationale of the "BIO-OHS" study (Prevalence of Obesity Hypoventilation Syndrome):
The overall prevalence of Obesity Hypoventilation Syndrome (OHS) has never been directly assessed in the general population. Actually, this prevalence has been assessed in patients referred to sleep clinics with a potential diagnosis of sleep-disordered breathing or in patients already diagnosed with sleep apnea. The purpose of this study is to determine the prevalence of Obesity Hypoventilation syndrome in obese patients referred to clinical laboratories for regular follow-up medical analysis.
No additional description
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| [HCO3-] >= 27 mmol/L (Group 1) | Other | All obese patients with plasmatic[HCO3-] >= 27 mmol/L will be addressed to a pneumologist. The pneumology investigations will establish(or not) the diagnosis of OHS |
|
| [HCO3-]< 27mmol/L+pneumologist (Group 2) | Other | Among obese patients with serum [HCO3-]< 27 mmol/L, 300 randomized patients will be addressed to a pneumologist. The pneumology investigations will refute(or not)the diagnosis of OHS. |
|
| [HCO3-]< 27 mmol/L (Group 3) | Other | Obese patients with a [HCO3-]<27 mmol/L randomized to group 3 will receive usual medical follow-up (end of study) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Blood test analysis in the clinical labs | Procedure | for specific measurement of plasmatic bicarbonate |
|
| Measure | Description | Time Frame |
|---|---|---|
| Prevalence of Obesity Hypoventilation Syndrome (OHS) in obese subjects referred to clinical laboratories for regular blood test analysis. | OHS prevalence, validated by arterial blood gases analysis, will be assessed by the percentage of patients with OHS among all patients included in the study | From date of inclusion until the end of the study currently planned (up to 2 years) |
| Measure | Description | Time Frame |
|---|---|---|
| Sensitivity and specificity of plasmatic [HCO3-] to detect OHS | A ROC curve will determine if the threshold of 27 mmol/L has the best diagnostic value. Decision trees will show if the diagnostic value of plasmatic [HCO3-]could be optimized by a combination with other clinical parameters. | From date of inclusion to the end of the study currently planned (2 years) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Jean-Louis Pepin, Pr, PhD | University Hospital, Grenoble | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Cabinet de Pneumologie Grenoble SUD | Échirolles | France | ||||
| Laboratoire MEDIBIO Les Cedres |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D010845 | Obesity Hypoventilation Syndrome |
| ID | Term |
|---|---|
| D020181 | Sleep Apnea, Obstructive |
| D012891 | Sleep Apnea Syndromes |
| D001049 | Apnea |
| D012120 | Respiration Disorders |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Pneumologist consult to establish the diagnosis of OHS | Procedure | complete respiratory check-up: Arterial blood gases analysis, spirometry, anthropometry, polygraphy or polysomnography. Medical history, previous treatments. |
|
| Prevalence of metabolic and cardiovascular comorbidities in patients with OHS | Prevalence will be estimated by the percentage and the confidence interval. Prevalences of metabolic and cardiovascular comorbidities among patients with OHS and without OHS will be compared by a KHI-2 test or Fisher Exact depends on the theorical number. | From date of inclusion to the end of the study currently planned (2 years) |
| To determine which medical specialties referred patients with OHS to clinical labs | estimated by percentage | From date of inclusion to the end of the study currently planned (2 years) |
| Incidence of serious health events at 1 and 2-year follow-up | Cardiovascular, metabolic and respiratory events (measured by percentages in OHS group and non-OHS group) will be compared by logistic regressions. | From time of OHS diagnostic to 1 and 2-year follow-up |
| Échirolles |
| France |
| Hôpital Michallon, Laboratoire EFCR et Sommeil | Grenoble | France |
| Cabinet de Pneumologie Perpignan | Perpignan | France |
| Laboratoire d'analyses medicales de Thuir | Thuir | France |
| D012140 |
| Respiratory Tract Diseases |
| D007040 | Hypoventilation |
| D012131 | Respiratory Insufficiency |
| D020919 | Sleep Disorders, Intrinsic |
| D020920 | Dyssomnias |
| D012893 | Sleep Wake Disorders |
| D009422 | Nervous System Diseases |
| D009765 | Obesity |
| D050177 | Overweight |
| D044343 | Overnutrition |
| D009748 | Nutrition Disorders |
| D009750 | Nutritional and Metabolic Diseases |